- CRS Publications
- News
News
Authors:
Date:
Business Wire: May 17, 2017 – MILPITAS, CA, U.S.A. – Elixir Medical Corporation, a developer of products that combine state-ofthe-art medical devices with advanced pharmaceuticals, today announced excellent 5-year clinical data from the DESolve Nx international pivotal clinical trial for the CE…
Authors:
Date:
Business Wire: May 16, 2017 – PARIS, France – Final 5-year outcomes from the DIRECT first-in-man study were presented at the EuroPCR symposium today, with 0% clinically driven target lesion revascularization (TLR), target vessel failure (TVF), and major adverse cardiac events (MACE) reported. The…
Authors:
Date:
PRNewswire: May 16, 2017 – PARIS, France – Micell Technologies announced today at the late-breaking trial session of EuroPCR— the official congress of the European Association of Percutaneous Cardiovascular Interventions—positive 12 month data from its DESSOLVE III clinical trial. The study met its…
Authors:
Date:
PRNewswire: May 13, 2017 – KANSAS CITY, KS, U.S.A. – Cingulate Therapeutics, LLC, a privately held biopharmaceutical company focused on the development of new and innovative products for the treatment of attention deficit/hyperactivity disorder (ADHD), is proud to announce its transition to a…
Date:
PRNewswire: March 23, 2017 – BOSTON, MA, U.S.A. – Newborns are highly vulnerable to infections and don’t respond optimally to most vaccines because their young immune systems typically mount weak antibody responses. Now, researchers at Boston Children’s Hospital report achieving strong vaccine…
Authors:
Date:
PRNewswire: March 23, 2017 – CAMBRIDGE, MA, U.S.A. – Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the enrollment of its first patient in a phase 1 study of MM-310 in solid tumors. MM-310 is an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and targets the…
